Eisbach Bio GmbH

About Eisbach Bio GmbH

Eisbach Bio GmbH is a clinical-stage biotechnology company based in Munich, Germany, focused on precision oncology. Founded in 2019, the company develops innovative drugs targeting synthetic lethality and molecular vulnerabilities in cancer cells, aiming to disrupt tumor genome reorganization with allosteric therapies. Their mission is to create transformative, safe, and selective cancer treatments with fewer side effects.

Products & Services

EIS-12656:A first-in-class allosteric small molecule inhibitor targeting ALC1 (CHD1L), a chromatin remodeling enzyme critical for DNA repair in cancer cells. It addresses homologous recombination deficient (HRD) tumors, suppresses PARP inhibitor resistance, and shows potential for combination therapies.

EIS-10700:A small molecule helicase inhibitor targeting nucleic acid helicases, initially developed for SARS-CoV-2 but also part of oncology research. It has completed Phase I trials with excellent safety profiles.

ALC1 Inhibitors:Selective drugs targeting ALC1 to induce synthetic lethality in HR-deficient tumors, potentiate PARP inhibitors, and enable combination therapies with a wide therapeutic window.

CHD1 Inhibitors:Allosteric inhibitors targeting CHD1 for synthetic lethality in PTEN-deficient cancers, with potential immunomodulatory effects in oncology.

Nuclear Helicase Inhibitors:Allosteric drugs targeting DNA-dependent nuclear helicases essential in specific genetic tumor contexts, offering novel therapeutic avenues for defined cancer populations.

SARS-CoV-2 Antivirals (e.g., EIS4363):Small molecule inhibitors targeting SARS-CoV-2 helicase Nsp13 to suppress viral replication, developed as sustainable COVID-19 therapies.

Specialties

Synthetic Lethality Allosteric Drug Development Chromatin Remodeling DNA Damage and Repair Pathways Genome Reorganization Nuclear Helicase Inhibition Precision Oncology Therapies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 4750000 MR: - FA: US$4.75 million FAN: 4750000	D: 2024-11-26 FD: 2024-11-26	1 investors
2	RT: Investment T: - FT: Investment	A: 4500000 MR: - FA: 4.5 million FAN: 4500000	D: 2024-03-21 FD: 2024-03-21	1 investors

Grant Latest

2024-11-26

$4.8M

1 investor (Pro only)

Investment 2024-03-21

$4.5M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Celia Schell

Clinical Operations

W

William Menzer

Medicinal Chemistry & CMC

M

Markus Lechner

Preclinical

D

Dana Matzek

Animal Models

X

Xin Zhang

Cancer Biology

L

Lucas Kalczynski

Preclinical

View 16 more team members with Pro

Unlock Full Team Directory

Recent News

Eisbach Bio GmbH Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised